Piper Sandler analyst Matt O’Brien lowered the firm’s price target on OrthoPediatrics (KIDS) to $22 from $30 and keeps an Overweight rating on the shares after the company preannounced Q3 revenue results that missed the firm and Street’s estimates by 6%/4%. The company also lowered full-year revenue and long-term growth rate expectations. While the update is frustrating, Piper believes management is “kitchen-sinking” its revenue outlook to get to a place it can meet and likely exceed in the future in order to start getting credit from a stock perspective. Consequently, the firm would take advantage of likely weakness in the stock.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KIDS:
- OrthoPediatrics: Strong Growth Prospects and Acquisition Potential Justify Buy Rating
- Closing Bell Movers: Levi Strauss down 8% after results
- OrthoPediatrics reports preliminary Q3 revenue $61.2M, consensus $63.63M
- OrthoPediatrics cuts FY25 revenue view to $233.5M-$234.5M from $237M-$242M
- OrthoPediatrics preliminary Q3 revenue $61.2M, consensus $63.63M